Wednesday, July 8, 2026
🇺🇸 FDA

biotech · Fabry Disease · Bioequivalence · PLX

Protalix Biotherapeutics

Protalix BioTherapeutics

Protalix Biotherapeutics patent portfolio — 22 USPTO pharmaceutical patents (A61K/A61P) with grant dates, status, and loss-of-exclusivity filters.

Website Investor relations
2 Snunit St., Science Park, POB 455, Carmiel, 2161401, IL, HACKENSACK, NJ, USA HQ
1994 Founded
197 Employees
Public company Type
PLX · NYSE Ticker
Company details
Status
Public
HQ
2 Snunit St., Science Park, POB 455, Carmiel, 2161401, IL, HACKENSACK, NJ, USA
Founded
1994
Employees
197
Programs
21
Drugs
14
Patents
22
Official website ↗ All projects Drug pipeline Patents News & analysis
Intelligence · Patents

Protalix Biotherapeutics patents

22 pharmaceutical patents indexed for Protalix Biotherapeutics. 0 expire within 24 months.

Protalix Biotherapeutics has 22 pharmaceutical patents in our USPTO PatentsView index (A61K/A61P). 0 expire within 24 months — use filters for patent-cliff planning.

All patents Expiring ≤12 months Expiring ≤24 months

22 patents

Patent portfolio

  1. US 12385026

    Stabilized alpha-galactosidase and uses thereof

    Expires Mon Aug 07 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. US 12194079

    Therapeutic regimen for the treatment of Fabry using stabilized alpha-galactosidase

    Expires Mon Jan 09 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. US 11814657

    Modified DNase and uses thereof

    Expires Mon Nov 09 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  4. US 11225648

    Modified DNase and uses thereof

    Expires Mon Jan 13 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  5. US 10870842

    Stabilized alpha-galactosidase and uses thereof

    Expires Mon Dec 17 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  6. US 10730925

    Chimeric polypeptides, polynucleotides encoding same, cells expressing same and methods of producing same

    Expires Mon Jul 30 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  7. US 10280414

    Stabilized α-galactosidase and uses thereof

    Expires Mon May 02 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  8. US 10087232

    Use of plant cells expressing a TNFalpha polypeptide inhibitor in therapy

    Expires Mon Sep 27 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  9. US 10000551

    Chimeric polypeptides, polynucleotides encoding same, cells expressing same and methods of producing same

    Expires Mon Jun 14 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  10. US 9732333

    Nucleic acid construct for expression of alpha-galactosidase in plants and plant cells

    Expires Mon Aug 10 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  11. US 9708595

    Stabilized alpha-galactosidase and uses thereof

    Expires Mon Jul 13 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  12. US 9603906

    Inhalable liquid formulations of DNase I

    Expires Mon Mar 23 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  13. US 9603907

    Dry powder formulations of dNase I

    Expires Mon Mar 23 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  14. US 9220737

    Plant cell culture expressing human lysosomal proteins and uses thereof

    Expires Mon Dec 24 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  15. US 9194011

    Stabilized alpha-galactosidase and uses thereof

    Expires Mon Nov 19 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  16. US 8790641

    Production of high mannose proteins in plant culture and therapeutic uses thereof

    Expires Mon Jul 24 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  17. US 8742079

    Saccharide-containing protein conjugates and uses thereof

    Expires Mon May 29 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  18. US 8741620

    Human lysosomal proteins from plant cell culture

    Expires Mon May 29 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  19. US 8449876

    Human lysosomal proteins from plant cell culture

    Expires Mon May 23 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  20. US 8227230

    Human lysosomal proteins from plant cell culture

    Expires Mon Jul 19 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  21. US 7951557

    Human lysosomal proteins from plant cell culture

    Expires Mon May 26 2031 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  22. US 7655781

    Variants of human glycoprotein hormone alpha chain: compositions and uses thereof

    Expires Mon Jan 28 2030 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

How many patents does Protalix Biotherapeutics have?

22 published patents match the current filter (all indexed). The full portfolio is indexed from USPTO PatentsView (A61K/A61P).

When do Protalix Biotherapeutics patents expire?

0 patents in the full portfolio expire within 24 months. Use the expiring filters above or open individual patent pages for grant and expiration dates.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.